Literature DB >> 1936106

Familial defective apo B-100, characterization of an Italian family.

A Corsini1, B J McCarthy, A Granata, L F Soria, S Fantappiè, C Romano, L Romano, R Fumagalli, A L Catapano.   

Abstract

Familial defective apolipoprotein (apo) B-100 is a genetic disorder presenting with hypercholesterolaemia and abnormal low-density lipoprotein (LDL) that binds poorly to LDL receptors. This disease appears to be caused by a mutation in the apo B-100 gene. In the present study thirteen members of a family with moderate hypercholesterolaemia (250-350 mg dl-1) were investigated. Biochemical studies on cultured skin fibroblasts ruled out classical familial hypercholesterolaemia (FH, receptor deficiency). We then studied the interaction between LDL and their receptors by an in vitro cell binding assay. LDL from nine affected members displayed a reduced affinity (2.5-fold) for the receptor, and were less effective than LDL from control and unaffected members in suppressing LDL receptor expression and in stimulating cholesterol esterification. LDL from the affected members had normal electrophoretic mobility, size and chemical composition. Partial delipidation did not modify the LDL binding defect. The disorder is transmitted over three generations as an autosomal codominant trait and all the affected members are heterozygotes and hypercholesterolaemics. Analysis of DNA from family members showed a point mutation leading to an Arg to Gln substitution at amino acid 3500 of the mature protein that segregated with hypercholesterolaemia and LDL defective binding. We conclude that this family is affected by familial defective apolipoprotein B-100 (FDB).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1936106     DOI: 10.1111/j.1365-2362.1991.tb01386.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  3 in total

1.  Absence of apolipoprotein B3500 mutation in type 2a hyperlipoproteinemia patients and in the general population from southern Italy.

Authors:  D Seripa; C Gravina; R Volpe; M Margaglione; S Papa; G Merla; P Parrella; G Di Minno; G Ricci; M Testa; V M Fazio
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

2.  Familial ligand-defective apolipoprotein B. Identification of a new mutation that decreases LDL receptor binding affinity.

Authors:  C R Pullinger; L K Hennessy; J E Chatterton; W Liu; J A Love; C M Mendel; P H Frost; M J Malloy; V N Schumaker; J P Kane
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

3.  Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease.

Authors:  Marta Valenza; Dorotea Rigamonti; Donato Goffredo; Chiara Zuccato; Simone Fenu; Laure Jamot; Andrew Strand; Alessia Tarditi; Ben Woodman; Marco Racchi; Caterina Mariotti; Stefano Di Donato; Alberto Corsini; Gillian Bates; Rebecca Pruss; James M Olson; Simonetta Sipione; Marzia Tartari; Elena Cattaneo
Journal:  J Neurosci       Date:  2005-10-26       Impact factor: 6.167

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.